Incidental C cell hyperplasia (CCH) following thyroidectomy for other indications may rarely be encountered, which may raise concerns about its clinical significance and proper management. CCH can be classified as physiological (reactive) or neoplastic. Reactive CCH has no malignant potential and can be observed in association with many other thyroid diseases (including differentiated thyroid cancer); in contrast, neoplastic CCH should be considered as a preneoplastic stage in the spectrum of C cell disease, ultimately leading to the development of medullary thyroid cancer (MTC). Neoplastic CCH is commonly observed in patients with germ-line mutations in the RET oncogene (commonly in families with a history of hereditary MTC, i.e. familial MTC or multiple endocrine neoplasia type 2 (MEN2)). CCH should be considered in patients with hypercalcitoninemia without nodular thyroidopathy. Total thyroidectomy, which is commonly performed for the majority of thyroid diseases, is an adequate treatment and achieves cure, even in patients with neoplastic CCH. There is no role for cervical lymph node dissection in patients with pure CCH. In conclusion, reactive CCH has no malignant potential, in contrast to neoplastic CCH. Total thyroidectomy achieves cure of patients with CCH.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000381605DOI Listing

Publication Analysis

Top Keywords

neoplastic cch
16
cch
11
cell hyperplasia
8
clinical significance
8
reactive cch
8
cch malignant
8
malignant potential
8
thyroid diseases
8
thyroid cancer
8
contrast neoplastic
8

Similar Publications

Canine cutaneous histiocytoma (CCH) represents a significant proportion of dog skin tumours, often manifesting as the most common neoplastic skin condition in young animals. Predominantly affecting dogs under four, these tumours appear primarily as solitary lesions that may regress spontaneously. This study, conducted over five years at the University of Trás-os-Montes e Alto Douro, involved a detailed histopathological and ultrastructural examination of 93 CCH cases.

View Article and Find Full Text PDF
Article Synopsis
  • Immunochemotherapy is currently the primary treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL), but it's ineffective for some patients, prompting research into better prognostic methods.
  • By analyzing transcriptomic data from a large group of patients, researchers identified seven distinct clusters of ndDLBCL, with one specific cluster (A7) linked to poorer outcomes due to characteristics like low immune cell presence and high MYC expression.
  • The study also explores how certain drugs, like lenalidomide, may improve treatment for the high-risk A7 cluster by enhancing T-cell movement into tumors and the expression of key tumor markers, while identifying TCF4 as a crucial factor in MYC biology for this group.
View Article and Find Full Text PDF

Immune checkpoint regulation is critically involved in canine cutaneous histiocytoma regression.

Front Vet Sci

June 2024

Institute of Veterinary Pathology, Faculty of Veterinary Medicine, Leipzig University, Leipzig, Germany.

Introduction: Canine cutaneous histiocytoma (CCH) is a benign tumor frequently occurring in young dogs which is derived from Langerhans cells (LC). Distinguishing features of this tumor are its spontaneous regression following a rapid tumor growth. Impaired control of immune checkpoints during tumor development and progression is a widespread phenomenon which may result in an absent or ineffective immune response.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers used a multiomic approach on tumor samples from 444 newly diagnosed DLBCL patients, combining gene analysis methods to identify a signature predictive of high early clinical failure risk.
  • * The study found that this signature, which includes ARID1A mutations, accurately predicted 45% of early clinical failures and could significantly influence future treatment strategies.
View Article and Find Full Text PDF

Enhancing the efficiency of lung cancer cell capture using microfluidic dielectrophoresis and aptamer-based surface modification.

Electrophoresis

June 2024

Department of Mechanical Engineering and Advanced Institute of Manufacturing for High-Tech Innovations, National Chung Cheng University, Chia-Yi, Taiwan, ROC.

Metastasis remains a significant cause to cancer-related mortality, underscoring the critical need for early detection and analysis of circulating tumor cells (CTCs). This study presents a novel microfluidic chip designed to efficiently capture A549 lung cancer cells by combining dielectrophoresis (DEP) and aptamer-based binding, thereby enhancing capture efficiency and specificity. The microchip features interdigitated electrodes made of indium-tin-oxide that generate a nonuniform electric field to manipulate CTCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!